AU2002216748A1 - Method of treatment of seborrheic dermatitis - Google Patents

Method of treatment of seborrheic dermatitis

Info

Publication number
AU2002216748A1
AU2002216748A1 AU2002216748A AU1674802A AU2002216748A1 AU 2002216748 A1 AU2002216748 A1 AU 2002216748A1 AU 2002216748 A AU2002216748 A AU 2002216748A AU 1674802 A AU1674802 A AU 1674802A AU 2002216748 A1 AU2002216748 A1 AU 2002216748A1
Authority
AU
Australia
Prior art keywords
lotion
cream
treatment
seborrheic dermatitis
ivermectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002216748A
Other languages
English (en)
Inventor
L. Dean Parks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DEAN PARKS DEAN L
Original Assignee
DEAN PARKS DEAN L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DEAN PARKS DEAN L filed Critical DEAN PARKS DEAN L
Publication of AU2002216748A1 publication Critical patent/AU2002216748A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2002216748A 2000-06-29 2001-06-27 Method of treatment of seborrheic dermatitis Abandoned AU2002216748A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/605747 2000-06-29
US09/605,747 US6319945B1 (en) 2000-06-29 2000-06-29 Method of treatment of seborrheic dermatitis
PCT/US2001/041159 WO2002002056A2 (en) 2000-06-29 2001-06-27 Method of treatment of seborrheic dermatitis

Publications (1)

Publication Number Publication Date
AU2002216748A1 true AU2002216748A1 (en) 2002-01-14

Family

ID=24425042

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002216748A Abandoned AU2002216748A1 (en) 2000-06-29 2001-06-27 Method of treatment of seborrheic dermatitis

Country Status (10)

Country Link
US (2) US6319945B1 (cg-RX-API-DMAC7.html)
EP (1) EP1294375B1 (cg-RX-API-DMAC7.html)
JP (1) JP3802485B2 (cg-RX-API-DMAC7.html)
CN (1) CN1171588C (cg-RX-API-DMAC7.html)
AT (1) ATE314068T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002216748A1 (cg-RX-API-DMAC7.html)
CA (1) CA2384448C (cg-RX-API-DMAC7.html)
DE (1) DE60116302T2 (cg-RX-API-DMAC7.html)
ES (1) ES2252312T3 (cg-RX-API-DMAC7.html)
WO (1) WO2002002056A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897559B2 (en) * 2000-06-29 2011-03-01 Parks L Dean Dermatological composition and kit containing avermectin compound for treating dermatological conditions
US6399651B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
KR101186271B1 (ko) 2002-06-26 2012-09-27 애버리 데니슨 코포레이션 폴리프로필렌/올레핀 탄성체 혼합물을 포함하는 배향된필름
FR2854074B1 (fr) 2003-04-24 2007-11-23 Galderma Res & Dev Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
WO2004093886A1 (en) * 2003-04-24 2004-11-04 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
FR2894823B1 (fr) * 2005-12-20 2008-02-29 Galderma Sa Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie
US9662867B2 (en) 2006-06-14 2017-05-30 Avery Dennison Corporation Conformable and die-cuttable machine direction oriented labelstocks and labels, and process for preparing
WO2007149900A2 (en) 2006-06-20 2007-12-27 Avery Dennison Corporation Multilayered polymeric film for hot melt adhesive labeling and label stock and label thereof
CA2666365C (en) * 2006-10-12 2016-08-09 Topaz Pharmaceuticals Llc Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice
US8901163B2 (en) 2007-01-03 2014-12-02 Galderma S.A. Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound
WO2012054328A1 (en) 2010-10-20 2012-04-26 Galderma S.A. Method of treating hemorrhoids using macrocyclic lactone compound
EP2629770B1 (en) 2010-10-20 2016-05-25 Galderma S.A. Ivermectin for use in treating otitis externa
US9782425B2 (en) 2013-07-08 2017-10-10 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
US9233117B2 (en) 2013-07-08 2016-01-12 Galderma S. A. Treatment of inflammatory lesions of rosacea with ivermectin
US11459488B2 (en) 2014-06-02 2022-10-04 Avery Dennison Corporation Films with enhanced scuff resistance, clarity, and conformability
CN110604741A (zh) * 2018-06-15 2019-12-24 瑞恩生化科技有限公司 抑制皮肤细胞增生的组合物及其应用
EP4062907A1 (fr) 2021-03-23 2022-09-28 Substipharm Formulation par voie orale d'ivermectine et utilisations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439924A (en) * 1991-12-23 1995-08-08 Virbac, Inc. Systemic control of parasites
US5877295A (en) * 1992-09-30 1999-03-02 The Center For Blood Research Antibodies which bind a subpopulation of Mac-1 (CD11b/CD18) molecules which mediate neutrophil adhesion to ICAM-1 and fibrinogen
DE4328689A1 (de) * 1993-08-26 1995-03-02 Beiersdorf Ag Verfahren zur Detektion und Zählung von Mikroorganismen
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5654312A (en) * 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
DE69739215D1 (de) * 1996-05-20 2009-03-05 Otsuka Pharma Co Ltd Heilmittel fuer rosazla
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
KR100315465B1 (ko) * 1998-11-23 2002-02-19 성재갑 수용성고분자와알코올을포함하는주사제용동물구충제조성물

Also Published As

Publication number Publication date
DE60116302D1 (de) 2006-02-02
EP1294375B1 (en) 2005-12-28
CA2384448C (en) 2008-09-16
CA2384448A1 (en) 2002-01-10
EP1294375A4 (en) 2004-06-09
ES2252312T3 (es) 2006-05-16
ATE314068T1 (de) 2006-01-15
CN1171588C (zh) 2004-10-20
WO2002002056A2 (en) 2002-01-10
US6433006B2 (en) 2002-08-13
JP3802485B2 (ja) 2006-07-26
US6319945B1 (en) 2001-11-20
US20020019354A1 (en) 2002-02-14
WO2002002056A3 (en) 2002-03-28
DE60116302T2 (de) 2006-08-10
EP1294375A2 (en) 2003-03-26
CN1383379A (zh) 2002-12-04
JP2004501939A (ja) 2004-01-22

Similar Documents

Publication Publication Date Title
EP1294375A4 (en) METHOD FOR THE TREATMENT OF SEBORRHOIC DERMATITIS
NZ318282A (en) Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
AU685075B2 (en) Pharmaceutical composition for treating nicotine dependence
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
AU6414994A (en) Composition and method for reducing toxicity of biologically-active factors
BR0014512A (pt) Tratamento tópico para infecções por estreptococos
HRP920632A2 (en) Oral composition for the treatment of inflammatory l deseases
CA2173457A1 (en) Use of 5-alpha reductase inhibitorsand compositions for treating androg enic alopecia
AU1809495A (en) Composition and method for preventing and treating inflammation with immunoglobulin a
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
MX9603596A (es) Perfluoropolieteres o composiciones de los mismos para prevencion y tratamiento de infecciones virales topicas.
JP2004501939A5 (cg-RX-API-DMAC7.html)
NZ326345A (en) Composition containing diosgenin
AU629445B2 (en) Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol
NO955084D0 (no) Estrensteroider som nevrokjemiske initiatorer for forandring i menneskets hypotalamiske funksjon og beslektede farmasöytiske blandinger og metoder
ZA969351B (en) Organic compositions
ZA9410143B (en) Psoriasis treatment
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
AU5521099A (en) Use of lithium gluconate for making a medicine for treating herpes and seborrheic dermatitis
WO2000019997A8 (en) Controlled release dosage from comprising oxybutynin
DE69331237D1 (de) Antiatherosclerotische mittel
NO870001L (no) Vehikel for nedsettelse av stroemning av terapaeutisk og kosmetisk farmakologisk aktive midler gjennom huden.
UA15180A (uk) Спосіб коhсервативhого лікуваhhя геhералізоваhого пародоhтиту